Search This Blog

Monday, June 2, 2025

Istanbul Talks Conclude As World Awaits Feared Massive Russian Military Response On Ukraine

 Despite Sunday's major Ukrainian drone operation deep inside Russian territory which is being called the country's Pearl Harbor, the second round of direct peace talks between Russia and Ukraine and coordinated by Turkey were held in Istanbul without a problem.

"The eyes of the whole world are focused on the contacts here," Turkish Foreign Minister Hakan Fidan told the delegations as the sides squared off in the opulent Çırağan Palace by the Bosphorus. Faden said the aim of the talks is to reach a "sustainable peace".

"We believe that you will achieve concrete results that will bring us one step closer to peace," Fidan added, stressing that the meeting aims to evaluate the conditions for a cease-fire, including prepare for a potential future meeting between the Russian and Ukrainian presidents. There's also the potential for more prisoner swaps to come out of the dialogue.

But expectations are low at this point, and it seems that the Kremlin is patiently weighing its options to Sunday's assault, rather launching a hasty retaliatory attack. 

One Turkish publication writes that even as talks happened, there are "no sign that the two sides are any closer to a deal, the mood in Russia was angry as the talks kicked off, with influential war bloggers calling on Moscow to deliver a fearsome retaliatory blow against Kyiv after Ukraine on Sunday launched one of its most ambitious attacks of the war, targeting Russian nuclear-capable long-range bombers in Siberia and elsewhere."

June 1, 2025: Russa's Pearl Harbor: "Russian bombers are burning en masse."

Russia’s delegation was again led Vladimir Medinsky, who arrived Sunday, while Ukraine’s team was headed by Defense Minister Rustem Umerov, and he had traveled Monday. Turkey’s intelligence chief Ibrahim Kalin also took part, according to RIA Novosti.

While Russia's precise proposals and terms for truce are as yet unclear, Reuters earlier previewed the Ukrainian side's as wanting a full 30-day ceasefire by air, land, and sea - followed by a return of all prisoners, and of the return of all Ukrainian children allegedly taken into Russian-held territory.

Overnight there were a small amount of Russian ballistic missiles fired on Ukraine, while on the other side the drone swarm attacks continued on Russia, resulting in fires:

Overnight Ukrainian drone attacks on the Kursk and Voronezh regions sparked fires in residential buildings and disrupted traffic on a major highway, regional officials said early on Monday.

Air defenses destroyed a total of 162 Ukrainian drones overnight, according to Russia's Defense Ministry, downing 57 of the aircraft over the Kursk region.

Falling debris from destroyed drones in the Kursk region sparked fires at several houses and damaged private apartments, Acting Kursk region Governor Alexander Khinshtein said.

Zelensky, feeling confident and emboldened, is warning Russia there's more to come as US and European weapons are 'better' and Kiev has a full arsenal of them. Clearly Zelensky attempted to establish leverage with 'Operation Spider Web'.

One Russian overnight attack reportedly killed 12 Ukrainian soldiers at a military base in Ukraine’s Dnipro region.

And as the dust settles from the major Sunday operation, it has become clear that Russia has lost hundreds of millions worth of military hardware, including several strategic bombers, now destroyed.

Satellite images emerge: "Judging by the images, four Tu-22M3 bombers and three Tu-95MS bombers were likely destroyed during the operation. In addition, one Tu-95MS was probably damaged," Ukraine media sources say.

Ukrainian President Volodymyr Zelensky had hailed the major Sunday attacks as "absolutely brilliant" and said that the planning for the operation had been in the works for a year-and-a-half. "Ukraine is defending itself, and rightly so – we are doing everything to make Russia feel the need to end this war," he said.

The White House has still yet to make a definitive statement, and weekend reports said that Kiev hid its planning from Washington - however many analysts expressed doubt over this claim. President Trump, if he embraces or hails the operation too enthusiastically, might derail efforts at improved bilateral relations with Russia. Any statement seen as giving a US 'blessing' might also serve to thwart ongoing ceasefire attempts.

https://www.zerohedge.com/geopolitical/istanbul-talks-conclude-feared-massive-russian-military-response-ukraine-hasnt-come

US Ambassador Calls For Establishment Of Palestinian State In France

 Via Remix News,

The new US ambassador to Israel, Mike Huckabee, has challenged France to match its advocacy for a Palestinian state by creating a new one on French soil. He suggested that France “carve off a piece of the Côte d’Azur,” also known as the French Riviera, for the establishment of such a state. This proposal has prompted an angry response from Paris.

During an interview with Fox News, Republican Huckabee stated, “If France is truly so determined to see a Palestinian state, I have a suggestion: Carve off a piece of the Côte d’Azur and establish a Palestinian state.”

He added that France was welcome to take such an action, but criticized “putting this kind of pressure on a sovereign nation,” referring to France’s stance toward Israel.

Huckabee contended that the events of Oct. 7, 2023 – the unprecedented attack by Hamas on Israel – “changed a lot.” He deemed France’s initiative at the United Nations to promote a Palestinian state “incredibly inappropriate” given that “Israel is in the middle of a war.”

France and Saudi Arabia are set to co-chair an international conference on the two-state solution.

While not explicitly stating whether France would recognize a Palestinian state, French President Emmanuel Macron declared on Friday that the “creation of a Palestinian state” under certain conditions was “not only a moral duty, but a political necessity.”

Macron also called for a tougher European stance and Western sanctions against Israel if the situation in the Gaza Strip does not improve soon. He may have a number of prominent backers, as European leaders increasingly call for action against Israel from a broad political spectrum. Notably, German Chancellor Friedrich Merz appears to be ready to increase pressure on Israel if the country continues blocking aid to Gazans. Other European leaders from Spain, Ireland, Norway, and a range of other countries, have already called for sanctions against Israel and the recognition of a Palestinian state.

In response, the Israeli government accused Macron of waging a “crusade against the Jewish state.”

Israeli Defense Minister Israel Katz announced on Friday that Israel would establish “a Jewish-Israeli state” in the West Bank, describing his declaration as a “decisive response to the terrorist organizations that seek to harm and weaken our control over this country.”

Katz further asserted that it was “a clear message” to “Macron and his partners”: “They will recognize a Palestinian state on paper – but we will establish the Jewish Israeli state here on this soil.”

Huckabee, known as a conservative hardliner, is a long-standing proponent of the Jewish settler movement in the West Bank, which has been deemed illegal by the United Nations.

Israel has seen the number of allies dwindle in Europe; however, countries like Hungary appear to have only increased support for Israel since Oct. 7. Recently, Orbán’s government left the International Criminal Court (ICC) in response to an arrest warrant for Prime Minister Benjamin Netanyahu, and other Israeli officials, for war crimes. Orbán also hosted Netanyahu on a state visit in Budapest at approximately the same time that he announced his country would leave the ICC.

https://www.zerohedge.com/geopolitical/us-ambassador-calls-establishment-palestinian-state-france

'Basel Medical Group Ltd Reaffirms Strong Financial Position Amid Market Volatility'

 Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today reaffirmed the strength of its underlying financial performance and strategic outlook, despite recent volatility in its share price.

Speaking on behalf of the Board and management team, BMGL’s Chief Executive Officer, Dr Darren Chhoa stated, “While recent movements in our share price may raise questions, I want to assure our shareholders and stakeholders that the fundamentals of BMGL remain strong and resilient. Our financial performance continues to be robust, with our subsidiaries winning new sizable contracts particularly in the supply chain, and we remain on track with our acquisition growth strategy.”

“We believe that the recent share price decline does not reflect the intrinsic value of our business nor the solid progress we’ve made. BMGL has consistently demonstrated strong operational execution, disciplined capital management, and a commitment to delivering sustainable value for shareholders.”

About Basel Medical Group Ltd

Basel Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments. Our operations are based in Singapore, with our clinics being at 6 Napier Road, Unit #02-10/11 and Unit #03-07, Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a large base of corporations, in particular those in the construction, marine and oil & gas industries, which underpin our robust business model. As an orthopedic service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage, government effort and expenditure on healthcare, growing sports participation rate and Singapore’s position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company’s website: www.baselmedical.com.

https://finviz.com/news/69113/basel-medical-group-ltd-reaffirms-strong-financial-position-amid-market-volatility

Vera Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial

 

  • Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)
  • Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continues
  • The safety profile of atacicept was favorable, and comparable to placebo
  • Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application (BLA) for accelerated approval to the FDA in 4Q 2025; ORIGIN 3 trial continues with two-year results expected in 2027
  • Vera will host a conference call and webcast at 8:00 am ET on Monday, June 2

For more information about the ORIGIN 3 clinical trial (NCT04716231), please visit http://www.clinicaltrials.gov.

The Company will host an investor call and webcast to discuss the data update at 8:00 AM ET on Monday, June 2.

Investors Dial-in: 1-877-425-9470
Int’l Investors Dial-in: 1-201-389-0878
Conference ID: 13754147
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1722931&tp_key=818ddad936

The live webcast will be available on the Company’s Investor Calendar, with the recording and presentation available immediately following the event.

https://finviz.com/news/71110/vera-therapeutics-announces-atacicept-achieved-46-proteinuria-reduction-in-origin-phase-3-trial-in-adults-with-iga-nephropathy

NewGenIvf Plans To Invest $30 Mln In Solana

 NewGenIvf Group (NIVF) announced plans to invest $30 million in staking the digital asset Solana. The investment will be funded through existing credit facilities of $26 million and $100 million with ATW and White Lion, respectively.

Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, said: "This investment represents a natural evolution of our digital asset strategy and positions us strategically within the burgeoning digital assets space. The decision to scale our investment from our initial $1 million Bitcoin position to this substantial $30 million Solana commitment reflects our growing conviction in digital assets as a legitimate asset class."

https://www.nasdaq.com/articles/newgenivf-plans-invest-30-mln-solana

Lyra Hits Endpoints in the Treatment of Chronic Rhinosinusitis

 

  • ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078)

  • ENLIGHTEN 2 trial also showed statistically significant improvement in key secondary endpoints in the full population of 3CS at 24 weeks (p=0.0209) and SNOT-22 score at 24 weeks (p=0.0101)

  • Additionally, in pooled data from ENLIGHTEN 2 and ENLIGHTEN 1 trials in 64 CRS patients with nasal polyps, LYR-210 demonstrated a consistent positive trend over 24 weeks in multiple key efficacy endpoints

  • Lyra plans to review the totality of the dataset from the ENLIGHTEN trials to evaluate next steps for pursuing an indication in non-polyp patients, as well as to continue development of LYR-210 in patients with nasal polyps  

  • Conference call to discuss trial results today at 8:30 a.m. ET
Lyra Therapeutics will host a conference call and webcast to discuss results from the ENLIGHTEN 2 trial today, June 2, 2025, beginning at 8:30 a.m. ET. To join the audio call please register via this audio link, or to view the livestreamed webcast visit this webcast link. A replay of the webcast and presentation will be available following the conference call in “Events and Presentations” in the Investors section of Lyra’s website for a limited time.

Sunday, June 1, 2025

FDA commissioner Dr. Marty Makary on "Face the Nation with Margaret Brennan," June 1

 MARGARET BRENNAN: Welcome back to Face the Nation. We're joined now by FDA Commissioner Dr. Marty Makary. Good morning. 

FDA COMMISSIONER DR. MARTY MAKARY: Good morning. 

MARGARET BRENNAN: Good to have you here in person. 

DR. MAKARY: Good to be here. 

MARGARET BRENNAN: So I want to get through a lot here, but one of the things we've noticed is this new COVID variant that seems to be circulating in Asia. I believe it's NB.1.8.1. It's a variant under monitoring. What do we need to know? 

DR. MAKARY: Yeah so this appears to be a subvariant of JN.1, which has been the dominant strain so it's believed that there is cross-immunity protection. The COVID- COVID virus is going to continue to mutate, and it's behaving like a common cold virus. It's now going to become the fifth coronavirus that's seasonal, that causes about 25% of the cases of the common cold.

MARGARET BRENNAN: So you're thinking of it as like a flu-type variant, just a normal fluctuation. 

DR. MAKARY: The flu mutates about 34 times more frequently than COVID. The COVID variant mutation rate appears to be a little more stable, but the international bodies that have provided some guidance on which strain to target, have suggested that either JN.1 or any of these subvariants would be reasonable strains to target.

MARGARET BRENNAN: So you don't seem overly concerned about that. I want to get now into some of the recommendations that have been very specific this week from the CDC and you with the HHS Secretary in this video announcement on Tuesday where Secretary Kennedy said the CDC was removing the COVID vaccine for healthy children and healthy pregnant women from its recommended immunization schedule. He then had a memo to the CDC rescinding recommendations for kids' vaccines, saying the known risks do not outweigh the benefits. Then late Thursday, the CDC said quote "shared clinical decision-making," which I think is just talking to your doctor should determine whether kids get vaccinated. Can you clearly state what the policy is? Because this is confusing. 

DR. MAKARY: Yeah, we believe the recommendation should be with a patient and their doctor. So we're going to get away from these blanket recommendations in healthy, young Americans because we don't want to see-- 

MARGARET BRENNAN: For all vaccines? 

DR. MAKARY: We don't- well on the COVID vaccine schedule, we don't want to see kids kicked out of school because a 12-year-old girl is not getting her fifth COVID booster shot. We don't see the data there to support a young, healthy child getting a repeat, infinite, annual COVID vaccine. There's a theory that we should sort of blindly approve the new COVID boosters in young, healthy kids every year in perpetuity, and a young girl born today should get 80 COVID mRNA shots, or other COVID shots in her average lifespan. We're saying that's a theory, and we'd like to check in and get some randomized, controlled data. It's been about four years since the original randomized trials, so we'd like an evidence based approach. Dr. Prasad and I published this in the New England Journal of Medicine last week, and we're basically saying we'd like to bring some confidence back to the public around this repeat booster strategy theory, because-- 

MARGARET BRENNAN: Your statement was not about repeat boosters. It says the vaccine is not recommended for pregnant women, the vaccine is not recommended for healthy children. That's different than annual boosters.

DR. MAKARY: Yeah at this point we're dealing, you know, it is a booster strategy- people would be getting the updated shot. So whether or not a young, healthy--

MARGARET BRENNAN: But what about kids who haven't gotten a shot?

DR. MAKARY: So we'd like to see the data. We'd love to see that- that data. It doesn't exist.

MARGARET BRENNAN: No, no, no, but on a practical level, for a parent at home, hearing you, trying to make sense here. 

DR. MAKARY: Yeah. We're saying, take it back to your doctor. 

MARGARET BRENNAN: Their child has not been vaccinated. Are you recommending that their first encounter with COVID be an actual infection?

(END CROSSTALK)

DR. MAKARY: We're not going to push the COVID shot in young, healthy kids without any clinical trial data supporting it. That is a decision between a parent and their doctor. And just so, I don't know if you know the statistics, but 80 for 88% of American kids, their parents, have said no to the COVID shot last season. So America, the vast majority Americans, are saying no. Maybe they want to see some clinical data as well. Maybe they have concerns about the safety--

MARGARET BRENNAN: I don't want to crowdsource my health guidance. I want a clear thing-- 

DR. MAKARY: The worst thing you--

MARGARET BRENNAN: --I wouldn't go with popularity--

DR. MAKARY: The worst thing--

MARGARET BRENNAN: --I'm going with, as you're saying, data-- 

DR. MAKARY: --Yeah so let's see the data.

MARGARET BRENNAN: Okay. So the CDC data said 41% of children aged six months to 17 years hospitalized with COVID between 2022 and 2024 did not have a known underlying condition. In other words, they looked healthy--

DR. MAKARY: So--

MARGARET BRENNAN: --and COVID was serious for them.

DR. MAKARY: So first of all, we know the CDC data is contaminated with a lot of false positives from incidental positive COVID tests with routine testing of every kid that walks in the hospital--

MARGARET BRENNAN: You don't trust the CDC data?

DR. MAKARY: --When I go to the ICU, when I walk to the P- the we know, We know that data, historically under the Biden administration, did not distinguish being sick from COVID or an incidental positive COVID test. When you go to an ICU in America and you ask, how many people are in the ICU that are healthy, that are sick with COVID, the answer I get again and again is, we haven't seen that in a year or years. And so the worst thing you can do in public health is to put out an absolute universal recommendation in young, healthy kids. And the vast majority of Americans are saying, no, we want to see some data. And you say, Forget about the data. Just get it anyway.

MARGARET BRENNAN: Okay, so on data and transparency for decades, since 1964 it was the Advisory Committee on Immunization Practices, ACIP that went through this panel recommendation. People watched these things during COVID. The report was then handed up. It offered debate, it offered transparency, and it offered data points that people could refer back to. Why did you bypass all of this and just come down with a decision before the panel could meet and meet that data? 

DR. MAKARY: That panel has been a kangaroo court where they just rubber stamp every single vaccine put in front of them. If you look at the minutes of the report from, they even say we were- generally want to move towards a risk stratified approach. 

MARGARET BRENNAN: So why not let them do that in June? 

DR. MAKARY: So in the meantime, we don't want an absolute recommendation for healthy kids to get it. They can do it, and that committee-committee will meet and make recommendations. But you look at the minutes of the last couple of years, they say we want a simple message for everybody, just so they can understand it. It was not a data based conversation. It was a conversation based on marketing and ease and and I've written an article titled "Why the people don't trust the CDC," and it's in part from that blanket strategy–

MARGARET BRENNAN: You're telling them not to right now. You just said don't trust the CDC. 

DR. MAKARY:  We're saying it's going to be between a doctor and a patient until that committee meets or more experts weigh in, or we get some clinical data. If there's zero clinical data, you're opining. I mean, you're just, it's a theory, and so we don't want to put out an absolute recommendation for kids with no clinical data at this point.

MARGARET BRENNAN: So you made this pronouncement as well on pregnant women. There is data. Researchers in the UK analyzed a series of 67 studies, which included 1.8 million women, and the journal BMJ Global Health published it. People can Google it at home, and it says the COVID vaccine in pregnant women is highly effective in reducing the odds of maternal SARS-CoV-2 infection, hospital admission and improves pregnancy outcomes with no serious safety concerns. This is data that shows that it is recommended or could be advised, for pregnant women to take this vaccine. Why do you find otherwise?

DR. MAKARY: There's no randomized control trial. That's the gold standard. Those 67 studies are mixed. The data in pregnant women is different for healthy versus women with a comorbid condition. So it's a very mixed bag. So we're saying your obstetrician, your primary care doctor, and the pregnant woman should together decide whether or not to get it. 12% of pregnant women last year got the COVID shot. So people have serious concerns, and it's probably because they want to see a randomized trial data, the randomized trial of pregnant women– 

MARGARET BRENNAN: But in the meantime, the world moves on, and you published in the New England Journal of Medicine on May 20. In that report, you referenced, you listed pregnancy as an underlying medical condition that increases a person's risk for severe COVID. You said that. So then seven days later, you joined in this video announcement saying you should drop the recommendation for the COVID vaccine in healthy pregnant women. So what changed in the seven days? 

DR. MAKARY: In the New England Journal medicine, we simply list what the f- what the CDC has traditionally defined as high risk, and we're just saying, decide with your doctor. We're not saying the other–

MARGARET BRENNAN: But doctors want data and information as well from you–

DR. MAKARY: and the randomized trial– so here's the data on pregnant women. A randomized control trial was set up, and it was closed without any explanation. We wanted to see that trial complete so women can have information that in a randomized control trial, which is the gold standard, this is what the data shows. We don't have those data. 

MARGARET BRENNAN: All right. It is still unclear what pregnant women now should do until they get the data that you say-- 

DR. MAKARY: I'd say talk to their doctor. 

MARGARET BRENNAN: When do they get the data you're promising? All these controlled studies.

DR. MAKARY: In the absence of data, they should talk to their doctor-- 

MARGARET BRENNAN: So no date?

DR. MAKARY: --and their doctor will use their best wisdom and judgment.

MARGARET BRENNAN: FDA Commissioner, thank you for trying to help clear this up. 

https://www.cbsnews.com/news/marty-makary-fda-commissioner-face-the-nation-transcript-06-01-2025/